| Summary: | <p><strong>Question:</strong><br />
In patients with type 2 diabetes, do sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduce risk for major kidney outcomes?</p><br />
<p><strong>Review Methods:</strong><br />
MEDLINE and Embase searched to Jun 2019 for English-language, randomized, controlled, event-driven trials that compared SGLT-2 inhibitors with placebo or an active comparator in adults with type 2 diabetes mellitus and assessed cardiovascular or kidney outcomes. Key exclusion: trials with extension periods.</p><br />
<p><strong>Included Studies:</strong><br />
4 randomized controlled trials (n = 38 723, mean age 63 to 64 y) met inclusion criteria and compared SGLT-2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) with placebo. All trials had low risk for bias for randomization sequence generation, allocation sequence concealment, blinding of patients and study personnel, and blinding of outcome assessors.</p><br />
<p><strong>Bottom Line:</strong><br />
In patients with type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes.</p>
|
|---|